ATE380807T1 - N-oxid von n-phenyl-2-pyrimidinaminderivaten - Google Patents

N-oxid von n-phenyl-2-pyrimidinaminderivaten

Info

Publication number
ATE380807T1
ATE380807T1 AT03731700T AT03731700T ATE380807T1 AT E380807 T1 ATE380807 T1 AT E380807T1 AT 03731700 T AT03731700 T AT 03731700T AT 03731700 T AT03731700 T AT 03731700T AT E380807 T1 ATE380807 T1 AT E380807T1
Authority
AT
Austria
Prior art keywords
derivatives
phenyl
pyrimidinemin
oxide
preparation
Prior art date
Application number
AT03731700T
Other languages
English (en)
Inventor
Klaus Boernsen
Peter End
Gerhard Gross
Ulrike Pfaar
Juerg Zimmermann
Paul William Manley
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9929594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE380807(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE380807T1 publication Critical patent/ATE380807T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
AT03731700T 2002-01-23 2003-01-22 N-oxid von n-phenyl-2-pyrimidinaminderivaten ATE380807T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0201508.9A GB0201508D0 (en) 2002-01-23 2002-01-23 Organic compounds

Publications (1)

Publication Number Publication Date
ATE380807T1 true ATE380807T1 (de) 2007-12-15

Family

ID=9929594

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03731700T ATE380807T1 (de) 2002-01-23 2003-01-22 N-oxid von n-phenyl-2-pyrimidinaminderivaten

Country Status (15)

Country Link
US (5) US7557105B2 (de)
EP (3) EP1470120B1 (de)
JP (2) JP4213595B2 (de)
KR (2) KR20070058019A (de)
CN (2) CN100467461C (de)
AT (1) ATE380807T1 (de)
BR (1) BR0307058A (de)
CA (1) CA2474104C (de)
DE (1) DE60318013T2 (de)
ES (2) ES2294293T3 (de)
GB (1) GB0201508D0 (de)
IL (2) IL162979A (de)
MX (1) MXPA04007130A (de)
PT (2) PT2194049E (de)
WO (1) WO2003062220A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60137273D1 (de) * 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
AU2004246800B2 (en) * 2003-06-13 2008-12-04 Novartis Ag 2-aminopyrimidine derivatives as Raf kinase inhibitors
AU2005283422C1 (en) * 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
EP1925941B1 (de) * 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Verfahren zur vorhersage der wirksamkeit eines vaskularisierungsinhibitors
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
CN101316590B (zh) * 2005-11-07 2011-08-03 卫材R&D管理有限公司 血管生成抑制剂和c-kit激酶抑制剂的组合使用
BRPI0620408B8 (pt) * 2005-12-21 2021-05-25 Novartis Ag derivados de pirimidinil aril uréia sendo inibidores de fgf, seus usos, e preparação farmacêutica
RU2448708C3 (ru) * 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
CA2662265A1 (en) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Imatinib compositions
EP1966186A1 (de) * 2006-10-26 2008-09-10 Sicor Inc. Verfahren zur herstellung von imatinib
EP2009008A1 (de) * 2006-10-26 2008-12-31 Sicor, Inc. Imatinib-Base und Imatinib-Mesylat und Herstellungsverfahren dafür
CN101225085B (zh) * 2007-01-17 2011-09-21 天津天士力集团有限公司 苯基呋咱氮类一氧化氮供体型2-苯胺嘧啶衍生物、其制备方法、含有该化合物的组合物及其用途
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
CN101245061B (zh) * 2007-02-13 2012-09-19 天津天士力集团有限公司 N-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-嘧啶胺类一氧化氮供体型衍生物，制备方法及其用途
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
US8242271B2 (en) 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
ES2607794T3 (es) 2007-06-07 2017-04-04 Intra-Cellular Therapies, Inc. Compuestos heterocíclicos novedosos y usos de los mismos
WO2008153959A1 (en) 2007-06-07 2008-12-18 Intra-Cellular Therapies, Inc. Novel heterocycle compounds and uses thereof
BRPI0817946A2 (pt) * 2007-09-25 2015-05-05 Teva Pharma Composições de imatinibe estável
KR101513326B1 (ko) * 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
AU2009210098B2 (en) * 2008-01-29 2013-06-13 Eisai R & D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
EP2255192A1 (de) * 2008-03-26 2010-12-01 Merck Patent GmbH Verfahren zur langzeitlagerung substratgekoppelter kügelchen
CN101417995B (zh) * 2008-11-21 2012-06-06 陈依军 苯氧基嘧啶衍生物及其制备方法和用途
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
WO2011162343A1 (ja) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
EP2997377B1 (de) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarker zur vorhersage und beurteilung der reaktion von endometriumkarzinompatienten auf lenvatinibverbindungen
CN103588754B (zh) * 2013-11-04 2015-05-27 遵义医学院 伊马替尼的制备方法
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
EP3624800A4 (de) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. Behandlung von leberzellkarzinom
CN107573322A (zh) * 2017-09-06 2018-01-12 南京优科生物医药研究有限公司 伊马替尼双氮氧化物、其制备方法和用途
CN109761970B (zh) * 2019-01-26 2020-06-09 中国药科大学 一种蛋白靶向降解嵌合分子、制备方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4607041A (en) * 1983-04-27 1986-08-19 Fisons Plc Antihypertensive 2-phenyl Hantzsch dihydropyridines
TW225528B (de) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
DE4444288A1 (de) * 1994-12-13 1996-06-20 Rainer Dr Med Etzel Verwendung von Weihrauch zur Behandlung der Alzheimer-Krankheit
WO1996026726A1 (en) * 1995-02-28 1996-09-06 Hoechst Marion Roussel, Inc. Pharmaceutical composition for piperidinoalkanol compounds
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
US7279576B2 (en) * 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments

Also Published As

Publication number Publication date
EP1783126A2 (de) 2007-05-09
CN100467461C (zh) 2009-03-11
JP2005519908A (ja) 2005-07-07
IL208399A (en) 2013-02-28
US20050209452A1 (en) 2005-09-22
KR100778163B1 (ko) 2007-11-28
JP4213595B2 (ja) 2009-01-21
IL162979A (en) 2010-12-30
EP2194049A1 (de) 2010-06-09
CN101468984A (zh) 2009-07-01
KR20040081467A (ko) 2004-09-21
EP1783126A3 (de) 2008-11-26
CA2474104A1 (en) 2003-07-31
CA2474104C (en) 2012-04-17
US7557105B2 (en) 2009-07-07
ES2503734T3 (es) 2014-10-07
WO2003062220A1 (en) 2003-07-31
JP2009051837A (ja) 2009-03-12
US20090239879A1 (en) 2009-09-24
US20140323494A1 (en) 2014-10-30
IL208399A0 (en) 2010-12-30
GB0201508D0 (en) 2002-03-13
EP2194049B1 (de) 2014-08-13
ES2294293T3 (es) 2008-04-01
DE60318013D1 (de) 2008-01-24
BR0307058A (pt) 2004-12-28
US20100222362A1 (en) 2010-09-02
EP1470120B1 (de) 2007-12-12
DE60318013T2 (de) 2008-11-13
PT1470120E (pt) 2008-03-03
JP5027076B2 (ja) 2012-09-19
KR20070058019A (ko) 2007-06-07
PT2194049E (pt) 2014-11-10
MXPA04007130A (es) 2004-10-29
CN1646519A (zh) 2005-07-27
US20110294820A1 (en) 2011-12-01
EP1470120A1 (de) 2004-10-27

Similar Documents

Publication Publication Date Title
ATE380807T1 (de) N-oxid von n-phenyl-2-pyrimidinaminderivaten
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
IL163090A (en) Nicotinamide derivates, pharmaceutical compositions comprising them and their use for manufacture of medicaments useful as p38 inhibitors
ATE556713T1 (de) Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
ATE454378T1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
ATE555789T1 (de) Pyridazinderivate und deren verwendung als therapeutische mittel
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
ATE532772T1 (de) Piperazinderivate und deren verwendung als therapeutische mittel
ATE515277T1 (de) Zusammensetzungen und verfahren zum beschichten von medizinischen implantaten
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
TW200510297A (en) Substituted n-aryl heterocycles, process for their preparation and their use as medicaments
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
DE50310516D1 (de) Fredericamycin-derivate
ATE508114T1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
NO20045056L (no) Fremgangsmater for behandling av hepatitt
CY1105221T1 (el) Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
DE60212146D1 (de) Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ATE358485T1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
MXPA05004621A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes.
IS6925A (is) Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1470120

Country of ref document: EP